effects, such as statin type, or its use as pretreatment. 2 In patients with stroke, the benefit of previously being on statin treatment on stroke outcome is well known. 3 To assess whether these benefits might be useful in acute stroke, we conducted a pilot clinical trial, in which patients receiving simvastatin improved significantly by the third day. 4 Some concerns exist about the use of statins after intravenous thrombolysis. In fact, a meta-analysis has reported an association between statins and increased fatality in studies restricted to tissue-type plasminogen activator (tPA)-treated patients, 5 which together with the increased rates of intracerebral hemorrhage among patients treated with statins in the SPARCL trial (Stroke Prevention by Aggressive Reduction in Cholesterol Levels), 6 call for further evidence about whether the association of statins and tPA may promote hemorrhagic transformation (HT). The STARS trial (Stroke Treatment With Acute Reperfusion and Simvastatin) was conducted to demonstrate the efficacy of simvastatin treatment in acute stroke and the safety of combining it with tPA.
Methods
The STARS trial was a multicentre, phase IV, prospective, randomized, double-blind, placebo-controlled trial carried out in 18 Spanish hospitals. The study protocol was approved by the Spanish National Drug Agency (EudraCT: 2007-005868-26) and by the local Ethics Committee of each center. A detailed list of the inclusion and exclusion criteria is included in Appendix I in the online-only Data Supplement. All participants or relatives gave written informed consent before randomization.
Patients were randomized (1:1) to receive either simvastatin or placebo treatment. A complete description of the randomization process and the study procedures is supported in Appendix II in the online-only Data Supplement. Patients, site investigators, and treating physicians were not informed about treatment allocation. Primary outcome was proportion of patients with good outcome (mRS score, ≤2) 90 days after stroke. Secondary outcomes were NIHSS (National Institutes of Health Stroke Scale) reduction at 90 days and proportion of patients with neurological improvement (decrease in NIHSS score, ≥4) at 7 days. Safety outcomes were symptomatic hemorrhagic transformation according to the ECASS-II criteria (European Cooperative Acute Stroke Study), 7 any HT on follow-up neuroimaging, hemorrhagic events, infections, death, and serious adverse events. Given the high percentage of patients treated with intravenous tPA, as post hoc analyses, we further analyze data on safety and efficacy in this subgroup of patients. In addition, neurological deterioration (increase of the NIHSS ≥4 points) and major neurological improvement (NIHSS score of 0 or decrease in the NIHSS score, ≥8) were assessed at 7 days.
Efficacy analyses were performed by intention-to-treat in patients who completed the follow-up and repeated in patients fulfilling criteria for per-protocol analysis. Given that some patients were missed to follow-up, sensitivity analysis was conducted by assuming the best (mRS≤2) and worst (mRS≤2) primary outcome for these patients as well as the best and the worst possible scenario for simvastatin treatment. Safety analyses were performed in every patient taking any dose of the study medication. Odds ratios (ORs) and 95% confidence intervals were obtained by logistic regression analyses, referred to simvastatin treatment. For safety analyses, crude OR were given, whereas for efficacy analyses, OR were adjusted by age, sex, and baseline NIHSS (adjusted OR). Statistical Package for Social Sciences (SPSS) Software v.17 was used. All analyses were performed blinded to treatment allocation. Details about sample size determination are given in Appendix II in the online-only Data Supplement. This study is registered with ClinicalTrials.gov, number NCT01073007.
Results
From April 2009 to March 2014, 104 patients were included, being randomized to either placebo (54 patients) or simvastatin (50 patients). Figure 1 shows the study flow chart. Median time to first treatment administration was 7.4 hours. Nasogastric tubes were needed in 9 cases. Two patients missed 1 dose of the study medication because of dysphagia and negative reaction to nasogastric tube placement. Demographic data are summarized in the Table. Figure 2 ). Sensitivity analysis did not change these results. There were no significant differences in secondary outcomes, and per-protocol analysis showed similar results (Tables I through II in the online-only Data Supplement). Regarding safety, there were no significant differences in the rate of HT between simvastatin and placebo arms (6 [ 49 ). There were no differences in other safety concerns except for a trend toward reduced incidence of serious adverse events in simvastatin arm. There were no cases of recurrent stroke or myocardial infarction on 3 months of follow-up. None of the serious adverse events in the simvastatin arm were considered related to the study medication. A complete description of all serious adverse events is available at Appendix III in the online-only Data Supplement.
Efficacy analyses conducted in the subgroup of patients receiving tPA showed no significant differences in the prespecified end points (Table III in 
Discussion
Our study did not show any effect of simvastatin treatment in acute stroke in terms of improvement in neurological or functional outcome. Previous studies have shown a beneficial effect of statin pretreatment, 3 and small clinical trials have shown inconsistent results, with either improved outcomes 4, 8 or no effects. 9, 10 Our results are limited by the failure to recruit the needed number of patients, with less than one third of those planned. A changing paradigm on statins in cardiovascular diseases, in which finding patients with stroke not on statin therapy could be difficult, represents one of the main causes for that. Moreover, the fact that the role of statins as a secondary prevention therapy has been demonstrated also represent an important cause for the low recruitment rate, as some physicians were not comfortable with the possibility of having patients without statins for the study period. Given the current role of statins in secondary stroke prevention, future trials on patients with stroke might be restricted to the first days after stroke, allowing statins according to the guidelines beyond this point.
One of the main strengths of our study is that it was designed, as suggested by the Stroke Treatment Academy Industry Roundtable (STAIR) recommendations, 11 taking into account the results of the whole evidence on experimental stroke. 2 In fact, simvastatin was the drug associated with higher infarct volume reduction and neurological improvement; pretreatment with statins achieved the biggest infarct reductions; and timing of administration was one of the factors that most influenced the results, features that were taken into account in the design of the STARS trial.
Our study is to our knowledge the first combining statins and tPA in acute stroke. The question of how statins could influence the rates of HT has not been answered by observational studies. 5 Simvastatin initiation in the acute stroke phase is not associated with higher rates of HT, and these safety results are still present when only patients treated with tPA are considered. Regarding symptomatic intracranial hemorrhage, differences were absent in our trial, even with favorable trends to simvastatin therapy. In fact, an increase in the sample size ≤431 patients would be required to demonstrate superiority of simvastatin over placebo. This results altogether might support the design of a future prehospital trial with simvastatin, as a potential neuroprotective role for both ischemic and hemorrhagic stroke, and therefore with the opportunity of being given at the ambulance. Another more restrictive strategy would be to conduct a large trial only in patients receiving reperfusion therapies, which are the ones that seem to benefit in our study. These data, however, should be carefully interpreted, as being based on just 55 patients treated with tPA.
In conclusion, although the STARS trial was underpowered to detect a beneficial effect of simvastatin therapy in acute stroke, the administration of simvastatin combined with tPA in patients with acute stroke seems to be safe and not associated with increased rates of HT. Therefore, this promising combination merits the effort of a large-scale international clinical trial in the near future.
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SUPPLEMENTAL MATERIAL
COMBINATION OF THROMBOLYSIS AND STATINS IN ACUTE STROKE IS SAFE. RESULTS FROM THE STROKE TREATMENT WITH ACUTE REPERFUSION AND SIMVASTATIN (STARS) RANDOMISED TRIAL
Randomization and masking
Patients were randomized (1:1) to receive either simvastatin or placebo treatment. A single randomization list was generated for 400 patients by computer software simulating the extraction process of numbered balls and their correlative allocation to each arm. Randomization was carried out by block (ten subjects per block), thereby ensuring a balanced number of subjects per treatment centre. To ensure allocation concealment, simvastatin and placebo had identical appearance (produced by the pharmaceutical company Uriach Group under current manufacturing rules (GMP) and ISO standard certificates). The randomization sequence was generated by the pharmacology department of the coordinating centre. Patients were enrolled by the site investigators following consecutive codes. Patients, site investigators and treating physicians were not informed of treatment allocation.
Procedures
Study medication was started immediately after study inclusion, within 12 hours after onset. Simvastatin was given at a dose of 40mg orally in the absence of dysphagia, or by nasogastric tube otherwise. The study medication was then administered once daily with the dinner for 90 days. Treatment adherence was defined as compliance with all the doses corresponding to the first week and ≥80% of the medication during follow-up. th days (or at hospital discharge, if earlier), and at 90 days after stroke. Vitals (blood pressure, temperature), stroke severity assessed with the NIHSS, treatment compliance, and adverse events were evaluated at every visit. Neuroimaging data (infarct presence and location, old vascular lesions, HT) were recorded at baseline and at follow-up neuroimaging, performed before the 7 th day/discharge visit. Stroke etiology, according to the TOAST (Trial of Org 10172 in Acute Stroke Treatment) classification, was assessed in the 7 th day/discharge visit. In the final visit, functional status using the mRS was evaluated. Clinical information was recorded by certified investigators blinded to treatment allocation.
Power estimates
Based on the results of the MISTICS Trial, a sample size of 340 patients was estimated sufficient to achieve 80% power to detect significant differences in the percentage of patients with good or poor neurological outcome at 90 days, assuming a functional independence rate of 35% in the placebo and 50% in the simvastatin arm. This sample size, considering that 10% of patients would be treated with tPA, would also demonstrate the safety of the combination of tPA and simvastatin regarding HT.
eAPPENDIX III. ADVERSE EVENTS
The table shows the total number of adverse events or serious adverse events, reported in both simvastatin and placebo arms, divided into one, two or more in each patient and serious adverse events by affected systems. 
